Genzyme Honors Innovation in Gaucher Disease Research through Its 2012 Gaucher Generation Program Awards
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced the recipients of the 2012 Gaucher Generation Program awards, an annual program in its fifth year that awards scientists and clinicians engaged in innovative Gaucher disease research.
Genzyme's Gaucher Generation program provides funding to researchers throughout the world to stimulate and support the advancement of medical knowledge in Gaucher disease. An independent committee of international Gaucher disease experts reviewed the research proposals and selected the most meritorious applications. This year, two "New Investigator Awards" were given, with each recipient receiving $100,000 over two years, as well as one "Established Investigator Award" with an award of $150,000 over two years.
"The Gaucher Generation Program represents Genzyme's ongoing commitment to enhance care and support of the global Gaucher community, with the ultimate goal of transforming the lives of patients," said Genzyme's Senior Vice President and Head of Rare Diseases, Rogerio Vivaldi, MD. "As world-renowned thought leaders, each of these recipients will make a meaningful contribution to further the understanding of Gaucher disease. Genzyme has been committed to serving the Gaucher community for over 20 years, and we are proud to support these award recipients in their important work."
This year's recipients are:
New Investigator Awards:
Gustavo Tiscornia, PhD, Assistant Professor in the Department of Biomedical Sciences and Medicine and Center for Molecular and Structural Biomedicine at the University of Algarve, Faro, Portugal. Dr. Tiscornia's project is entitled "Development of an induced pluripotent stem cell model of neuronopathic Gaucher's Disease for investigating mechanisms of pathogenesis and small molecule testing." Dr. Tiscornia will focus on the use of stem cells to study Gaucher disease type 2, which involves the nervous system.
Elena Pavlova, MD, PhD, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK. In Dr. Pavlova's project entitled, "Lymphoma in Gaucher disease - studies of causation and potential cure," she will focus her efforts to better understand why patients with Gaucher disease have an increased risk of cancer.
Established Investigator Award:
Pramod K Mistry, MD, PhD, Professor of Pediatrics and Internal Medicine, Chief, Pediatric Hepatology, and Director, National Gaucher Disease Treatment Center at Yale University School of Medicine, New Haven, Conn., USA. Dr. Mistry's project is entitled "Studies to delineate specific phenotypes of Gaucher disease and decipher respective biomarker signatures and genetic underpinnings." Dr. Mistry will seek to better understand how genes impact clinical and biochemical manifestations in patients with Gaucher disease.
For the 2012 application year, an international committee of Gaucher disease experts scored the research proposals. Submissions were considered on the basis of scientific merit, adequacy of the experimental design, and feasibility of the proposed study. Higher consideration was given to proposals that had the potential for improving patient outcomes. The judges were blinded to the identity of the applicants until final decisions were made. More information on Genzyme's Gaucher Generation Program, including previous recipients, can be found at: http://www.gauchercare.com/healthcare/generation.aspx.
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme's portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world's largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at www.genzyme.com.
Genzyme® is a registered trademark of Genzyme Corporation. All rights reserved.
Ingrid Esser, 617-768-6699
KEYWORDS: United States North America Massachusetts
The article Genzyme Honors Innovation in Gaucher Disease Research through Its 2012 Gaucher Generation Program Awards originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.